Article
Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
PloS one - 1 Jan 2017
Kuracha Murali R, Thomas Peter, Loggie Brian W, Govindarajan Venkatesh
Abstract excerpt
Mucinous colorectal adenocarcinomas (MCAs) are clinically and morphologically distinct from nonmucinous colorectal cancers (CRCs), show a distinct spectrum of genetic alterations (higher KRAS mutations, lower p53, high MUC2), exhibit more aggressive behavior (more prone to peritoneal dissemination and lymph node involvement) and are associated with poorer response to chemotherapy with limited treatment options....
Topics
- Cell Line, Tumor
- Cell Survival
- Colorectal Neoplasms
- Enzyme Activation
- Gene Expression Regulation, Neoplastic
- Humans
- MAP Kinase Signaling System
- Mitogen-Activated Protein Kinase Kinases
- Molecular Targeted Therapy
- Mucin-2